Fine Foods & Pharmaceuticals N.T.M. SpA (FF) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 3.14%

Poor long term growth as Operating profit has grown by an annual rate 187.54% of over the last 5 years
Low ability to service debt as the company has a high Debt to EBITDA ratio of 2.21 times

Flat results in Dec 21

With ROE of 9.07%, it has a Expensive valuation with a 1.47 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

EUR 214 Million ()

P/E

16.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.09

Return on Equity

9.09%

Price to Book

1.55

Revenue and Profits:

Net Sales:

66 Million

(Quarterly Results - Jun 2025)

Net Profit:

5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

11.82%

6 Months

27.79%

1 Year

24.87%

2 Years

20.44%

3 Years

18.55%

4 Years

-34.4%

5 Years

-10.14%

Fine Foods & Pharmaceuticals N.T.M. SpA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.39%

EBIT Growth (5y)

187.54%

EBIT to Interest (avg)

1.77

Debt to EBITDA (avg)

2.21

Net Debt to Equity (avg)

0.32

Sales to Capital Employed (avg)

0.76

Tax Ratio

29.27%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

3.14%

ROE (avg)

2.06%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.47

EV to EBIT

13.42

EV to EBITDA

7.29

EV to Capital Employed

1.35

EV to Sales

1.01

PEG Ratio

0.02

Dividend Yield

ROCE (Latest)

10.02%

ROE (Latest)

9.07%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 14.66% vs -7.43% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 176.47% vs 136.96% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "65.70",
          "val2": "57.30",
          "chgp": "14.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "10.40",
          "val2": "7.10",
          "chgp": "46.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.80",
          "chgp": "-25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4.70",
          "val2": "1.70",
          "chgp": "176.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "97.40%",
          "val2": "56.10%",
          "chgp": "4.13%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -3.18% vs 21.70% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 334.29% vs 63.16% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "243.80",
          "val2": "251.80",
          "chgp": "-3.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "29.40",
          "val2": "22.00",
          "chgp": "33.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.40",
          "val2": "5.00",
          "chgp": "-32.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-3.80",
          "chgp": "97.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "8.20",
          "val2": "-3.50",
          "chgp": "334.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "56.00%",
          "val2": "23.20%",
          "chgp": "3.28%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

65.70

57.30

14.66%

Operating Profit (PBDIT) excl Other Income

10.40

7.10

46.48%

Interest

0.60

0.80

-25.00%

Exceptional Items

0.00

Consolidate Net Profit

4.70

1.70

176.47%

Operating Profit Margin (Excl OI)

97.40%

56.10%

4.13%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 14.66% vs -7.43% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 176.47% vs 136.96% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

243.80

251.80

-3.18%

Operating Profit (PBDIT) excl Other Income

29.40

22.00

33.64%

Interest

3.40

5.00

-32.00%

Exceptional Items

-0.10

-3.80

97.37%

Consolidate Net Profit

8.20

-3.50

334.29%

Operating Profit Margin (Excl OI)

56.00%

23.20%

3.28%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -3.18% vs 21.70% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 334.29% vs 63.16% in Dec 2023

All Annual Results

Company CV

About Fine Foods & Pharmaceuticals N.T.M. SpA

Fine Foods & Pharmaceuticals N.T.M. SpA

Pharmaceuticals & Biotechnology

Fine Foods & Pharmaceuticals NTM SpA, formerly Innova Italy 1 SpA, is an Italy-based pharmaceutical company. It is specialized in the manufacturing of pharmaceutical products for third parties. The Company manages three segments: Pharmaceuticals, Nutraceuticals and Medical Devices. The Pharmaceuticals segment includes powders and granules, tablets, coated tablets and hard gelatin capsules, packaged in sachets, blisters and bottles. The Nutraceuticals segment includes soluble and effervescent powders and granules, soluble, effervescent and chewable tablets, coated tablets and hard gelatin capsules packaged in bags, sachets, sticks, jars, tablet bottles, blisters and strips. The Medical Devices segment includes tablets, capsules, powders, granules and cover the areas for gastrointestinal, oral and throat treatment and the weight management. Medical Devices marked CE (European Conformity) are available for licensing.

Company Coordinates

Company Details

Via Berlino, 39, Zingonia , VERDELLINO None : 24040

Tel:

http://www.finefoods.it/

Registrar Details